December 19, 2016 07:24 AM EST

Editas fires back at CRISPR/Cas9 rivals, bagging an exclusive license to a tech upgrade

John Carroll

Editor & Founder

Just days after biotech rivals formed an IP alliance around CRISPR/Cas9 gene editing tech, Editas Medicines $EDIT has fired back in their patent war …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Editas fires back at CRISPR/Cas9 rivals, bagging an exclusive license to a tech upgrade

John Carroll

Editor & Founder

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

New study will try to stop Alzheimer’s decades before it begins, using experimental Eli Lilly drug

Amgen announces hold on Phase 1 obesity candidate, pipeline cuts

We’re about to find out which RFK Jr. will show up at HHS

Astellas shakes up management despite impressive nine-month earnings

Merck CEO says he’s confident in growth despite Gardasil ‘headwind’

Ed­i­tas fires back at CRISPR/Cas9 ri­vals, bag­ging an ex­clu­sive li­cense to a tech up­grade

Editor & Founder

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Editas fires back at CRISPR/Cas9 rivals, bagging an exclusive license to a tech upgrade